Knight Therapeutics Inc. (GUD.TO)
CAD 6.17
(0.65%)
CAD 6.17
(0.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 10.33 Million CAD | 71.57% |
| 2022 | 6.02 Million CAD | 113.38% |
| 2021 | -45 Million CAD | 74.05% |
| 2020 | -173.4 Million CAD | -61.93% |
| 2019 | -107.08 Million CAD | 56.25% |
| 2018 | -244.78 Million CAD | 50.69% |
| 2017 | -496.46 Million CAD | 3.59% |
| 2016 | -514.94 Million CAD | -116.84% |
| 2015 | -237.48 Million CAD | 16.22% |
| 2014 | -283.44 Million CAD | -28344545000.0% |
| 2013 | -1.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.25 Million CAD | -29.73% |
| 2024 Q2 | -2.69 Million CAD | -137.18% |
| 2023 Q4 | 10.33 Million CAD | 124.61% |
| 2023 Q2 | 41.35 Million CAD | 56.54% |
| 2023 Q1 | 26.41 Million CAD | 338.78% |
| 2023 Q3 | 4.59 Million CAD | -88.88% |
| 2023 FY | 10.33 Million CAD | 71.57% |
| 2022 Q3 | -62.75 Million CAD | -14.3% |
| 2022 Q2 | -54.9 Million CAD | 17.65% |
| 2022 FY | 6.02 Million CAD | 113.38% |
| 2022 Q1 | -66.66 Million CAD | -48.14% |
| 2022 Q4 | 6.02 Million CAD | 109.59% |
| 2021 Q1 | -229.32 Million CAD | -32.25% |
| 2021 Q4 | -45 Million CAD | 13.41% |
| 2021 Q3 | -51.97 Million CAD | 17.11% |
| 2021 Q2 | -62.69 Million CAD | 72.66% |
| 2021 FY | -45 Million CAD | 74.05% |
| 2020 Q3 | -170.24 Million CAD | 41.09% |
| 2020 Q4 | -173.4 Million CAD | -1.86% |
| 2020 FY | -173.4 Million CAD | -61.93% |
| 2020 Q2 | -288.98 Million CAD | -45.97% |
| 2020 Q1 | -197.97 Million CAD | -84.87% |
| 2019 FY | -107.08 Million CAD | 56.25% |
| 2019 Q4 | -107.08 Million CAD | 66.34% |
| 2019 Q3 | -318.12 Million CAD | -8.24% |
| 2019 Q2 | -293.9 Million CAD | -27.76% |
| 2019 Q1 | -230.04 Million CAD | 6.02% |
| 2018 Q4 | -244.78 Million CAD | 19.27% |
| 2018 Q2 | -418.35 Million CAD | 28.29% |
| 2018 Q1 | -583.4 Million CAD | -17.51% |
| 2018 FY | -244.78 Million CAD | 50.69% |
| 2018 Q3 | -303.22 Million CAD | 27.52% |
| 2017 Q2 | -527.87 Million CAD | -1.61% |
| 2017 Q4 | -496.46 Million CAD | 2.05% |
| 2017 FY | -496.46 Million CAD | 3.59% |
| 2017 Q1 | -519.52 Million CAD | -0.89% |
| 2017 Q3 | -506.83 Million CAD | 3.99% |
| 2016 Q2 | -363.71 Million CAD | -77.61% |
| 2016 Q3 | -389.4 Million CAD | -7.06% |
| 2016 Q4 | -514.94 Million CAD | -32.24% |
| 2016 FY | -514.94 Million CAD | -116.84% |
| 2016 Q1 | -204.78 Million CAD | 13.77% |
| 2015 Q3 | -246.6 Million CAD | 25.05% |
| 2015 FY | -237.48 Million CAD | 16.22% |
| 2015 Q4 | -237.48 Million CAD | 3.7% |
| 2015 Q2 | -329.04 Million CAD | -9.21% |
| 2015 Q1 | -301.29 Million CAD | -6.3% |
| 2014 Q4 | -283.44 Million CAD | -24.74% |
| 2014 Q2 | -234.5 Million CAD | -221.47% |
| 2014 Q3 | -227.22 Million CAD | 3.11% |
| 2014 Q1 | -72.94 Million CAD | 0.0% |
| 2014 FY | -283.44 Million CAD | -28344545000.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | -1.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | -8.64 Million CAD | 219.45% |
| Avicanna Inc. | 1.32 Million CAD | -678.918% |
| Avant Brands Inc. | 17.93 Million CAD | 42.387% |
| Cardiol Therapeutics Inc. | -34.77 Million CAD | 129.707% |
| Crescita Therapeutics Inc. | -8.13 Million CAD | 227.045% |
| MediPharm Labs Corp. | -15.68 Million CAD | 165.855% |
| OrganiGram Holdings Inc. | -33.7 Million CAD | 130.645% |
| Canopy Growth Corporation | 512.87 Million CAD | 97.986% |
| Willow Biosciences Inc. | -989 Thousand CAD | 1144.489% |
| Auxly Cannabis Group Inc. | 142.88 Million CAD | 92.77% |